Compare Agilent Technologies Inc (A) vs Infosys Limited (INFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Infosys Limited — how do they compare? Agilent Technologies Inc trades at $128.67 (market cap $37.04B), while Infosys Limited trades at $11.03 (market cap $46.00B). The key difference: Infosys Limited is the larger of the two by market cap, and Infosys Limited pays the higher dividend (4.65%). Which is the better fit depends on your goals.
| A | INFY | |
|---|---|---|
Market Cap | $37.04B | $46.00B |
Sector | Health | Technology |
52-Week High | $157.20 | $20.22 |
52-Week Low | $110.24 | $10.49 |
Enterprise Value | $38.59B | $43.21B |
Dividend Yield | 0.78% | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
INFY trades at $10.88, down 2.51% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 16.44% and ROE of 31.57% for 2025, while recent earnings have mostly beaten expectations. Analyst consensus is a 'Hold' with a $13.18 price target, suggesting potential upside. Recent news highlights multiple AI collaborations, such as with Sentara and GlobalFoundries, indicating strategic focus on AI-driven growth.
The outlook for INFY is mixed; fundamentals remain solid with steady revenue growth and high profitability, but technical indicators and sector-wide demand concerns pose near-term risks. The stock presents a value opportunity given its low P/E of 13.6, though investors face volatility from competitive pressures and macroeconomic headwinds affecting IT spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
